1. Executive Summary (Confidence: High)

Neurosoft Bioelectronics is addressing one of the most critical bottlenecks in the field of neural engineering: the mechanical mismatch between rigid electronics and the soft, moving tissue of the human brain.^[23] Spun out of EPFL and based at Campus Biotech in Geneva, the organization produces interfaces that are 100,000 times softer and 5 times thinner than traditional neural probes.^[23] This innovation allows for minimally invasive implantation, significantly reduced scarring, and access to deep cortical areas such as the brain sulci.^[23]

In February 2026, the company entered a major multiyear partnership with Science Corporation, granting it access to a world-class clinical-grade BCI technology stack.^[27] This partnership accelerates the company’s ability to scale its proprietary "NeuroAI" and foundational brain models.^[27] With lead programs in epilepsy mapping and the first BCI-based treatment for severe tinnitus (SOFT TINNIT), Neurosoft is positioned to redefine the treatment of chronic neurological injury.^[26]